Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Special Report
Aust Covid Vaccine Tracker

Posted 20 November 2020

Gilead Australia has hit back at a World Health Organisation move to recommend doctors stop using the company's Veklury as a treatment for COVID-19.

While the WHO said a trial it sponsored, Solidarity, found "there is currently no evidence that [Veklury] improves survival or the need for ventilation", Gilead disagreed. The WHO experts also reviewed data from three other trials to conclude remdesivir has "no meaningful effect" on time to clinical improvement.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios